ANN ARBOR, Mich., Sept. 14, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, will present safety and efficacy data from a 12-month study of patients with dilated cardiomyopathy treated with the company’s cell therapy product, ixmyelocel-T. Results will be presented on September 19, 2011, in a poster presentation at the 15th Annual Heart Failure Society of America Scientific Meeting in Boston, Massachusetts.
